About Amarillo Biosciences (OTCMKTS:AMAR)
Amarillo Biosciences, Inc. is engaged in the business of biopharmaceutical research and development. The Company develops biologics for the treatment of human and animal diseases. The Company's focus is research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia and other indications using natural human interferon alpha that is administered in a low dose oral form. The Company owns or licenses approximately two issued patents related to the low-dose oral delivery of interferon and it owns an issued patent on its dietary supplement, Maxisal. It has a pending patent, which applies low dose oral interferon to the treatment of Thrombocytopenia.
Industry, Sector and Symbol
Trailing P/E Ratio-1.36666666666667
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value($0.04) per share
Price / Book-1.03
Return on EquityN/A
Return on Assets-162.53%
Amarillo Biosciences (OTCMKTS:AMAR) Frequently Asked Questions
What is Amarillo Biosciences' stock symbol?
Amarillo Biosciences trades on the OTCMKTS under the ticker symbol "AMAR."
How were Amarillo Biosciences' earnings last quarter?
Amarillo Biosciences Inc (OTCMKTS:AMAR) issued its quarterly earnings data on Monday, November, 20th. The company reported ($0.01) earnings per share (EPS) for the quarter. View Amarillo Biosciences' Earnings History.
When will Amarillo Biosciences make its next earnings announcement?
Who are some of Amarillo Biosciences' key competitors?
Some companies that are related to Amarillo Biosciences include RXi Pharmaceuticals (RXII), OpGen (OPGN), Bioblast Pharma (ORPN), Avinger (AVGR), Sunshine Heart (CHFS), ESSA Pharma (EPIX), Strata Skin Sciences (SSKN), Secure Point Technologies (IMSC), Mateon Therapeutics (MATN), Neurometrix (NURO), Lombard Medical (EVARF), Rosetta Genomics (ROSG), TearLab (TEAR), Delcath Systems (DCTHD), Dextera Surgical (DXTR), BG Medicine (BGMD), Affymax (AFFY) and Tetralogic Pharmaceuticals (TLOG).
Who are Amarillo Biosciences' key executives?
Amarillo Biosciences' management team includes the folowing people:
- Stephen T. Chen Ph.D., Chairman of the Board, Chief Executive Officer (Age 64)
- Bernard Cohen, Chief Financial Officer, Vice President, IR Contact Officer (Age 60)
- Yasushi Chikagami, Director (Age 75)
- Marian Tibbits, Director (Age 57)
- Paul Tibbits, Director (Age 74)
How do I buy Amarillo Biosciences stock?
Shares of Amarillo Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amarillo Biosciences' stock price today?
One share of Amarillo Biosciences stock can currently be purchased for approximately $0.04.
How big of a company is Amarillo Biosciences?
Amarillo Biosciences has a market capitalization of $5.79 million. The company earns $-660,000.00 in net income (profit) each year or ($0.03) on an earnings per share basis. Amarillo Biosciences employs 4 workers across the globe.
How can I contact Amarillo Biosciences?
Amarillo Biosciences' mailing address is 4134 BUSINESS PARK DRIVE, AMARILLO TX, 79110. The company can be reached via phone at 806-376-1741 or via email at [email protected]
MarketBeat Community Rating for Amarillo Biosciences (AMAR)MarketBeat's community ratings are surveys of what our community members think about Amarillo Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Amarillo Biosciences (OTCMKTS:AMAR) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Amarillo Biosciences (OTCMKTS:AMAR) Earnings History and Estimates Chart
Amarillo Biosciences (OTCMKTS AMAR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/13/2018|| || || || || || || || |
Amarillo Biosciences (OTCMKTS:AMAR) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Amarillo Biosciences (OTCMKTS:AMAR)
No dividend announcements for this company have been tracked by MarketBeat.com
Amarillo Biosciences (OTCMKTS AMAR) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 0.01%
Amarillo Biosciences (OTCMKTS AMAR) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/9/2018||Bernard H Cohen||VP||Buy||10,199||$0.25||$2,549.75|| |
|11/13/2017||Stephen T Chen||CEO||Buy||203,000||$0.19||$38,570.00|| |
|10/17/2017||Stephen T Chen||CEO||Buy||6,000||$0.25||$1,500.00|| |
|9/26/2017||Stephen T Chen||CEO||Buy||6,000||$0.27||$1,620.00||3,045,206|| |
|9/18/2017||Stephen T Chen||CEO||Buy||3,000||$0.28||$840.00||3,045,206|| |
|9/13/2017||Stephen T Chen||CEO||Buy||1,000||$0.27||$270.00||3,045,206|| |
|9/6/2017||Stephen T Chen||CEO||Buy||6,000||$0.28||$1,680.00||3,045,206|| |
|8/30/2017||Stephen T Chen||CEO||Buy||3,000||$0.27||$810.00||3,045,206|| |
|8/24/2017||Stephen T Chen||CEO||Buy||2,739||$0.27||$739.53||3,045,206|| |
|8/22/2017||Stephen T Chen||CEO||Buy||6,000||$0.27||$1,620.00||3,045,206|| |
|8/11/2017||Stephen T Chen||CEO||Buy||3,000||$0.29||$870.00||3,045,206|| |
|7/24/2017||Stephen T Chen||CEO||Buy||2,000||$0.28||$560.00||3,045,206|| |
|7/12/2017||Stephen T Chen||CEO||Buy||4,000||$0.29||$1,160.00||3,045,206|| |
|7/5/2017||Stephen T Chen||CEO||Buy||2,000||$0.28||$560.00||3,045,206|| |
|6/29/2017||Stephen T Chen||CEO||Buy||4,105||$0.28||$1,149.40||2,969,111|| |
|6/23/2017||Stephen T Chen||CEO||Buy||4,500||$0.26||$1,170.00||2,969,111|| |
|6/20/2017||Stephen T Chen||CEO||Buy||4,000||$0.25||$1,000.00||2,969,111|| |
|6/19/2017||Stephen T Chen||CEO||Buy||2,000||$0.25||$500.00||2,969,111|| |
|6/12/2017||Stephen T Chen||CEO||Buy||2,000||$0.25||$500.00||2,969,111|| |
|6/8/2017||Stephen T Chen||CEO||Buy||1,000||$0.27||$270.00||2,969,111|| |
|6/6/2017||Stephen T Chen||CEO||Buy||1,000||$0.26||$260.00||2,969,111|| |
|5/31/2017||Stephen T Chen||CEO||Buy||1,000||$0.25||$250.00||2,969,111|| |
|5/19/2017||Stephen T Chen||CEO||Buy||1,000||$0.25||$250.00||2,969,111|| |
|5/11/2017||Stephen T Chen||CEO||Buy||1,000||$0.26||$260.00||2,969,111|| |
|4/25/2017||Stephen T Chen||CEO||Buy||2,000||$0.27||$540.00||2,969,111|| |
|4/20/2017||Stephen T Chen||CEO||Buy||9,000||$0.24||$2,160.00||2,969,111|| |
|4/14/2017||Stephen T Chen||CEO||Buy||2,000||$0.24||$480.00||2,969,111|| |
|4/7/2017||Stephen T Chen||CEO||Buy||5,000||$0.24||$1,200.00||2,969,111|| |
|4/5/2017||Stephen T Chen||CEO||Buy||3,000||$0.24||$720.00||2,969,111|| |
|4/3/2017||Stephen T Chen||CEO||Buy||4,000||$0.23||$920.00||2,969,111|| |
|3/24/2017||Stephen T Chen||CEO||Buy||4,000||$0.22||$880.00||2,969,111|| |
|3/20/2017||Stephen T Chen||CEO||Buy||1,000||$0.25||$250.00||2,969,111|| |
|3/15/2017||Stephen T Chen||CEO||Buy||1,000||$0.23||$230.00||2,969,111|| |
|3/9/2017||Stephen T Chen||CEO||Buy||1,000||$0.25||$250.00||2,969,111|| |
|3/6/2017||Stephen T Chen||CEO||Buy||1,000||$0.23||$230.00||2,969,111|| |
|3/2/2017||Stephen T Chen||CEO||Buy||1,000||$0.25||$250.00||2,969,111|| |
|2/27/2017||Stephen T Chen||CEO||Buy||500||$0.25||$125.00||2,969,111|| |
|2/21/2017||Stephen T Chen||CEO||Buy||500||$0.23||$115.00||2,969,111|| |
|2/15/2017||Stephen T Chen||CEO||Buy||2,000||$0.24||$480.00||2,969,111|| |
|1/25/2017||Stephen T Chen||CEO||Buy||1,000||$0.25||$250.00||2,969,111|| |
|1/20/2017||Stephen T Chen||CEO||Buy||500||$0.28||$140.00||2,823,706|| |
|11/29/2016||Stephen T Chen||CEO||Buy||1,500||$0.24||$360.00||2,823,706|| |
|9/7/2016||Stephen T Chen||CEO||Buy||2,000||$0.16||$320.00||2,823,706|| |
|8/26/2016||Stephen T Chen||CEO||Buy||800,000||$0.12||$96,000.00||2,823,706|| |
|8/19/2016||Stephen T Chen||CEO||Buy||706||$0.18||$127.08||2,023,706|| |
|8/15/2016||Stephen T Chen||CEO||Buy||1,000||$0.19||$190.00||2,023,706|| |
|7/27/2016||Stephen T Chen||CEO||Buy||10,000||$0.20||$2,000.00||2,023,706|| |
|5/10/2016||Stephen T Chen||CEO||Buy||10,000||$0.16||$1,600.00||2,023,706|| |
|4/13/2016||Stephen T Chen||CEO||Buy||157||$0.20||$31.40||2,023,706|| |
|3/30/2016||Stephen T Chen||CEO||Buy||10,009||$0.18||$1,801.62||2,023,706|| |
|3/22/2016||Stephen T Chen||CEO||Buy||5,000||$0.18||$900.00||2,023,706|| |
|3/11/2016||Stephen T Chen||CEO||Buy||2,000||$0.18||$360.00||2,023,706|| |
|2/25/2016||Stephen T Chen||CEO||Buy||5,000||$0.18||$900.00||2,023,706|| |
Amarillo Biosciences (OTCMKTS AMAR) News Headlines
Amarillo Biosciences (OTCMKTS:AMAR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Amarillo Biosciences (OTCMKTS:AMAR) Income Statement, Balance Sheet and Cash Flow Statement
Amarillo Biosciences (OTCMKTS AMAR) Stock Chart for Wednesday, January, 17, 2018